$MRSN News
Last published 10mo ago
- 10mo agoDAWNMRSNDay One Completes Acquisition of Mersana TherapeuticsGlobeNewswireBRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of
- 12mo agoMRSNMersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial ResultsGlobeNewswireDay One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate
- 12mo agoMRSNDay One Biopharmaceuticals to Acquire Mersana TherapeuticsGlobeNewswireAgreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal
- 1y agoMRSNMersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025GlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers
- 1y agoMRSNMersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMRSNMersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial ResultsGlobeNewswireMore than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion
- 1y agoMRSNMersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025GlobeNewswireCAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers
- 1y agoMRSNMersana Therapeutics Announces 1-for-25 Reverse Stock SplitGlobeNewswireCAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers
- 1y agoMRSNMersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual MeetingGlobeNewswire31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy
- 1y agoMRSNMersana Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers
- 1y agoMRSNCORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsGlobeNewswireIn a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been
- 1y agoMRSNMersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsGlobeNewswireUpdated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving
- 1y agoMRSNMersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast CancerGlobeNewswireCost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and
- 1y agoMRSNMersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual CongressGlobeNewswireCAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireAnnounced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously treated with at least
- 1y agoMRSNMersana Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025GlobeNewswireCAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)GlobeNewswireCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 1y agoMRSNMersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast CancerGlobeNewswire- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously
- 1y agoMRSNMersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMRSNMersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsGlobeNewswirePlan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 13,
- 2y agoMRSNMersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024GlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMRSNMersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsGlobeNewswireDose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital
- 2y agoMRSNMersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024GlobeNewswireCAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMRSNMersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsGlobeNewswireMaximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion
- 2y agoMRSNMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024GlobeNewswireCAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireEnrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in
- 2y agoMRSNMersana Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024GlobeNewswireCAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoMRSNMersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireEnrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024Phase 1
- 2y agoMRSNMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 2y agoIMGNABBVXBI.NBI+6Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billionCNBCOther biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.
- 3y agoMRSNMersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoMRSNMersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsGlobeNewswireAdvancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana's B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana's HER2 Immunosynthen
- 3y agoMRSNMersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023GlobeNewswireCAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 3y agoMRSNMersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056GlobeNewswireCAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 3y agoMRSNMersana Therapeutics Announces Changes in LeadershipGlobeNewswireAnna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian
- 3y agoMRSNMersana Therapeutics Announces Second Quarter 2023 Financial ResultsGlobeNewswireOrganization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan commitments into 2026 CAMBRIDGE, Mass., Aug. 08,
- 3y agoMRSNMersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
- 3y agoMRSNMersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic ReprioritizationGlobeNewswireUPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., July 27, 2023